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Welcome to The University of New Mexico Department of Pathology’s 8th installment of PathFINDER! In this

1. W E LCOME FROM DOUGLAS P. CL ARK, MD

2 01 8

issue we join with TriCore Reference Laboratories in celebrating its 20th anniversary. Look inside for comments
3. FE ATURE : COMING FUL L CIRCL E W ITH PH-L IKE AL L

and reflections from some of the original founders. Through this unique collaboration we are able to provide
outstanding laboratory services to the people of New Mexico and beyond.

5. FE ATURE : TRICORE AT 20
Also in this issue is an inspiring story of how years of basic research by Drs. Cheryl Willman and Rick Harvey are
being translated into a commercial test at TriCore to identify high-risk leukemia patients. We will be the only site in
the world offering this important new diagnostic test.

10. INTRODUCING: NE W ME XICO WOME N IN PATHOLOGY PROFE SS I O NA L SO C I E TY
11. IN ME MORIAM: TOBY ME RL IN, MD

Please continue to follow us on Facebook, Instagram and Twitter!

12. UP COMING FACULTY TAL KS , NE W FACULTY ME MBE R S

Enjoy.

14. MAKE A GIFT

DOUGLAS P. CLARK, MD
Professor & The Frederick H. Harvey Chair of Pathology

Cover image details: TriCore before and after.
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FEAT UR E

unique world-class expertise in this area. The project also advanced our department’s educational and training
mission, as Molecular Pathology Fellow Joanna Conant, MD served as a crucial team member.

CO MI NG F U LL C IR C L E W IT H P H - LIK E ALL
BY DAVID R. CZUCHLEWSKI, MD

Thanks to their efforts, TriCore now offers a simple, inexpensive, and comprehensive approach to the diagnosis

ASSOCIATE PROFESSOR

of Ph-like ALL, starting with screening using the LDA assay. We then reflex as necessary to additional assays

MEDICAL DIRECTOR OF THE GENETICS AND CYTOMETRY LABORATORIES

including FISH rearrangements in high-incidence genes, a RNA gene fusion panel, and a multiplex next generation

TRICORE REFERENCE LABORATOR IES

sequencing panel evaluating a large number of genes known to be associated with Ph-like B-ALL. To assist
pathologists and clinicians in using this screening assay and diagnostic algorithm, each case is accompanied by an
integrated interpretive comment.

Alumni of the UNM Department of Pathology are likely familiar with a saga of discovery and clinical advances
relating to a novel subgroup of patients with acute lymphoblastic leukemia (ALL), driven by the team in the lab of
Cheryl Willman, MD – including Rick Harvey, PhD and I-Ming Chen, DVM. Their groundbreaking research, recently
featured on the front page of CAP Today (http://captodayonline.com/fresh-incentive-look-ph-like/), is now finding
widespread clinical application via a partnership in assay development with TriCore Reference Laboratories.

“Recognizing the need for widespread access to this
cost-effective and comprehensive screening assay, the
Hematopathology and Molecular Pathology team in our

Troubled by the persistence of a subset of patients with
B-ALL who experienced poor outcomes despite optimal riskadapted therapy, Willman’s group participated in a multiinstitutional effort known as the TARGET (Therapeutically

department worked with TriCore Reference Laboratories to
license and validate the LDA card assay, for the first time making
this “gold standard” test commercially available to any and all
patients.”

Applicable Research to Generate Effective Treatments)

DAVID R. CZUCHLEWSKI, MD

Project through the National Cancer Institute and the
Children’s Oncology Group. The data from UNM identified an
unusual cluster of patients with a gene expression signature
similar to that seen in patients with the BCR-ABL1 fusion

TriCore’s algorithm is the first commercially and clinically available option to screen for BCR-ABL1-like B-ALL, and it

(i.e., the Philadelphia chromosome), but lacking that specific

brings full circle the saga begun a decade ago in our department. Discovered here – and now tested here – Ph-like

rearrangement. Termed “BCR-ABL1-like,” or “Ph-like” ALL,

ALL is one of the most exciting stories in Hematopathology, and our department remains at the center of it all.

this new entity was found to be associated with a poor
prognosis and enriched for novel genetic rearrangements
and mutations potentially amenable to targeted therapy. Endorsed as a provisional diagnostic entity by the WHO

If you would like to send a case for Ph-like ALL testing, please see http://www.tricore.org/BCR_ABL1_like_ALL for
complete information, specimen requirements, and requisition form.

2016 classification, Ph-like ALL was the subsect of large scale clinical trials that have benefited thousands of
patients across the country.
However, outside of clinical trial setting, laboratory testing for Ph-like ALL has been challenging. As the WHO has
stated, “From a practical standpoint, it is difficult to identify these leukemias without complex laboratory analysis,
and it is also difficult to screen cases of B-ALL to determine which cases would need such analysis.” The Willman
lab developed a simplified gene expression assay using a “low density array” card, which uses up to 15 genes to
identify the characteristic features of the Ph-like signature. This assay has been used for thousands of clinical trial
patients, but was not readily available to other patients.
Recognizing the need for widespread access to this cost-effective and comprehensive screening assay, the
Hematopathology and Molecular Pathology team in our department worked with TriCore Reference Laboratories to
license and validate the LDA card assay, for the first time making this “gold standard” test commercially available
to any and all patients. The team, led by Director of Molecular Diagnostics Devon Chabot-Richards, MD, included
Mohammad Vasef, MD as the leader of the clinical validation study and Carla Wilson, MD, PhD. Dr. Wilson, who was
a member of the research team involved in the initial discovery of Ph-ALL, joined Dr. Harvey in leveraging UNM’s
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A N D R E W H O R VA T H , M D

FEAT UR E
TR I CO RE AT 2 0

CL INICAL P R OFESSOR , SECR ETARY-T R EASUR ER , PAT HOLOGY ASSO C I AT E S OF A LBU QU E RQU E

INTERVIEWS BY WILLIAM F. COLLINS, MFA
W HAT WAS THE MOTIVATION FOR CR EATING TR ICOR E?
TriCore Reference Laboratories turned 20 this year! We asked Michael Crossey, MD, PHD, Andrew Horvath, MD,

New Mexico, being a small state, critical volumes did not exist for each of the leading laboratories in the state

Mary Lipscomb Lyons, MD, and Steve McKernan about the motivating forces behind creating TriCore and the

to achieve a sufficient volume of lab tests to be able to provide high quality, extensive and efficient services.

challenges they faced along the way.

The University of New Mexico Hospitals and Presbyterian Hospitals, prior to the formation of TriCore Reference
Laboratories, established NMIL (New Mexico Immunology Laboratory) for immunogenetics and histocompatibility,

M I C H A E L C R O S S E Y, M D , P H D

which served both institutions. Even though they had competing transplant programs, it demonstrated that by

C EO, TRI CORE R E F E R E NCE LA BO R ATO RIE S

“Reference Laboratory” serving the outpatient population was a potentially better platform for attracting referral

combining volumes, quality services could serve both institutions. This has worked well for several years. The
work for centers of excellence at the University of New Mexico Hospital (such as hematopathology with Dr. Kathy

WHAT WAS THE MOT I VAT I O N FO R C R EATING TRICO RE ?

Foucar at the helm). There was also recognition that by combining the inpatient and outpatient services at Tricore

During the initial review by CHI Consulting it showed we were sending out to reference labs about 25-27% of our

and UNM, greater efficiencies could be achieved and overall quality would increase while significant cost savings

testing volume. By consolidating the labs we could strengthen the areas of Anatomic, Toxicology, Molecular (which

could be achieved. The administration of both institutions and the support of the pathologists over a two year

at the time was just forming), and especially Microbiology. As part of the 20th Birthday here at Tricore I have

period of planning created TriCore Reference Laboratories.

been going through the 1998 “Business and Implementation Plan for an
W HAT W ER E THE CHALLENGES IN M A K I N G T RI CORE A

Integrated Regional Laboratory Program” document. It’s very interesting.

R EALITY ?
W H AT WE RE TH E CH ALLE NG E S IN MAKING TRICO RE A

The biggest challenges were integration of information technology

R E A LITY?

platforms and to overcome the inherent resistance to change. Blending of

Integrating an I.T. system across both sponsors was and remains a

the cultures of the inpatient laboratories at The University of New Mexico

challenge. Standardizing test nomenclature and test menus wasn’t easy.

Hospital and Presbyterian Hospital, and the “Reference Laboratory” were

I believe we had initial “Culture” issues, but the way we had specific

also challenging, but with a lot of work we slowly integrated into one

service line work groups with technologists and pathologists from both

culture. Information technology remains an evergreen challenge, but with

institutions we brought both cultures together with a patient service

all of the new opportunities and demand that is not unusual.

focus. It wasn’t easy or fast, but it did work well for the long term.
HOW HAS TR ICOR E’S MISSION CHA N GE D OV E R T H E COU RS E
H OW H AS TRICO RE ’ S MISS IO N CH ANG E D OVE R TH E COUR SE

OF THE PAST 2 0 Y EAR S?

O F T HE PAST 20 YE ARS?

The mission has not really changed but we added applied research,

In spite of various changes to verbiage I believe we have maintained

laboratory management outside the sponsoring institutions and

our mission of leading the region in patient care, provider support and

population health management through laboratory information
technology. Our core mission remains to provide the highest quality of laboratory and pathology services at the

research and education.

lowest cost to the population of New Mexico while fulfilling the educational and research needs at The University of
New Mexico.

WHERE D O YO U E NV I S I O N T R I CO R E GOING IN TH E FUTURE ?
The lab’s mission is constant, but we have to grow and diversify to survive the constant pressures of dropping
reimbursements from CMS and private payers. So, our future has to include independent payments for Population

W HER E DO YOU ENVISION TR ICOR E GOING IN THE FUTUR E?

health analytics and Quality metrics aligned to Value based payment models. All areas of healthcare are looking at

Continue with our core competencies in laboratory medicine and pathology, increase our applied research

areas of waste and poor outcomes and trying to improve. We have to be able to show we can produce a valuable

capabilities, and possibly expand beyond our regional geography by partnering with some national enterprise for

informatics product that can address these issues and get paid separately from the clinical lab fee schedule.

other healthcare organizations to market our “diagnostic optimization,” predictive population health management

In addition we need to expand our Research Institute to leverage our Pathologists and Scientists working with IVD

program nationwide.

companies planning and developing the next generation of medical laboratory technology.
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M A R Y L I P S C O M B LY O N S , M D

render prognoses in regard to genetic and oncologic diseases. I believe that these initiatives continue.

PR O F E SSOR E ME R I T U S , T H E U NI V E R S I T Y O F NE W ME X ICO S CH O O L O F ME DICINE

W HER E DO YOU ENVISION TR ICOR E GOING IN THE FUTUR E?
I hope to learn that TriCore will continue to maintain its role as a provider of cost effective, excellent laboratory

WHAT WAS THE MOT I VAT I O N FO R C R EATING TRICO RE ?

medicine and that it will continue to educate pathology residents and medical technologists to become first

Certainly, different participants had different motivations. As the relatively new chair of pathology, my motivation

rate practitioners. I also hope that it will be a leader in the development of molecular tests and exploit its huge

to enthusiastically endorse the idea, which as I recall came from Andrew Horvath, was three fold: First, there was

population data base with cutting edge computer systems to assess relevant clinical outcomes for the state of New

a clear threat to local clinical laboratory practice from national labs that threatened the local control of laboratory

Mexico and the Southwest Region that TriCore serves. This, of course, will require the participation of UNM faculty

medicine. Thus, UNM and the Department of Pathology joining forces with other local health care systems and

and trainees with expertise in clinical outcomes research.

local pathologists to form a highly efficient and effective clinical laboratory seemed a necessary step to take to
best serve the New Mexico community in laboratory patient care. Second, developing a regional laboratory where
our residents could learn and participate in a larger, more varied practice than was available at our tertiary and
academic practice was important. Already, our residents had opportunities, particularly in anatomic pathology

STEVE MCKERNAN
FOR MER CEO, T HE UNIVER SIT Y OF NEW MEXICO HOSP ITAL

to experience community practice as well as a more academic practice, but clinical pathology training in a truly
regional laboratory was clearly a great opportunity. Third, already we were developing the concept of a very strong
consultative practice in hematopathology (lead by Dr. Kathy Foucar)

W HAT WAS THE MOTIVATION FOR CR EATING TR ICOR E?
Two reasons. The lab at UNMH was outdated and cramped and the CAP had issued a warning on the space. There

and did not have the infrastructure for the pick-up of specimens and
mechanisms of advertisement for the service. A regional laboratory with
a larger capacity for building and maintaining a first class consultative

was a plan to replace the lab with a free standing building next to the hospital along Lomas. The cost was very high
and the new building would have used up valuable land, which is now the Pavilion. The cost seemed excessive and
space was at a premium.

service would benefit our department financially as well as build more
opportunities for fellowship training.

The pathology department wished to expand its referral lab capability but did not have the space, facilities or
capabilities without a new lab building. Additionally the hospital would have had to invest in the infrastructure to

W H AT WE RE TH E CH ALLE NG E S IN MAKING TRICO RE A

support referrals, which would have been very expensive, with very low ROI to the hospital.

R E A LITY?
There were a great many challenges, but I will emphasize the most
important. We had to determine how much value each of the participating
organizations brought to the table and then to determine how we could
equitably come together so that each organization had the ability to
maintain sufficient control so that the potentially competing needs of

In discussion with Mary Lipscomb, which included outsourcing the lab,
it was decided to join a proposal by Andrew Horvath and PAA’s lab and
Presbyterian to determine if we could do a joint lab.
The third partner was St. Vincent’s lab, which Presbyterian was in the

community practices and an academic practice could be met. From

process of purchasing – i.e. the name TriCore.

the perspective of UNM, the most important conclusion to these discussions was that it would maintain a 50%
representation on the board and that the needs of the University to maintain its research and education programs
would be met. I give great credit to the UNM Hospital CEO at the time, Steve McKernan, in his willingness to
commit resources to the realization of this position and of the Presbyterian administration to accept it as the first
major hurdle that we all had to overcome to establish TriCore. There were other challenges, mostly logistical, but
each was met with a commitment of all partners in finding solutions to what sometimes seemed impossible hurdles.

W HAT W ER E THE CHALLENGES IN M A K I N G T RI CORE A
R EALITY ?
a. Developing a shared culture
b. Computer infrastructure
c. Leadership and management team development
d. Billing systems

HOW HAS TRI CO R E ’S MI SS I O N C H A N GE D OVE R TH E CO URS E O F TH E PAST 20 YE ARS?
Over TriCore’s first ten years during which I was on the Board, the mission to provide excellent laboratory medicine
for New Mexico and adjacent regions did not change. Furthermore, the commitment to provide excellent education
for not only residents in medicine, but medical technologists, continued to be an important part of TriCore’s
mission. It did increase its opportunities for research, and one of the leaders in this was Dr. Steve Young who was
always looking for opportunities for new strategies for diagnosing viral diseases. Other opportunities for clinical

e. Inadequate facility and multiple facilities
f. Development of a model that would work in multiple hospital and clinics
g. Cash
continues on page 9

relevant research focused on cutting edge technologies, particularly using molecular techniques to diagnose and
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INT R ODUC ING

continued from page 8

HOW HAS TRI CO R E ’S MI SS I O N C H A N GE D OVE R TH E CO URS E O F TH E PAST 20 YE ARS?
The mission has stayed the same, provide the best care and service to the patients of the partners. Provide superior

N EW MEXI CO WOMEN I N PATHOLOGY PR OF ESSION A L
SOCI ETY

service to the referral providers. Teach the future health providers for the State. Provide a venue to engage in
research for the benefit of the State’s citizens.
WHERE D O YO U E NV I S I O N T R I CO R E GOING IN TH E FUTURE ?
TriCore should be one of the most advanced pathology providers in supporting its partners in their care, teaching
and research missions. Be at the forefront of advancing pathology in providing the cutting edge science.
Pathology residents Drs. Brittney Coffman and Emily Wolak, along with faculty member Dr. Devon ChabotRichards, have taken the lead on developing the New Mexico Women in Pathology Professional Society. The
group is dedicated to providing a space for mentorship, networking and supporting women at all levels of training
practicing under the umbrella of pathology in New Mexico. Ultimately, NMWIPPS seeks to advance the full and
successful participation and inclusion of women in medicine and science by addressing gender equity, recruitment
and retention, awards and recognition, and career advancement.

You may reach the group via email: NMWIPPS@gmail.com

Follow NMWIPPS on Twitter
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IN ME M O R IA M

UPC OM ING FAC ULT Y TALKS

TO BY ME R LIN , M D

JA N UA RY - J ULY, 201 9

AUGUST 18, 1952 - AUGUST 18, 2018
KURT B. NOLTE, MD
It was with much sadness and heartfelt condolence that we passed along news of the death of Dr. Toby Merlin

Topic: Incorporation of Computed Tomography into Forensic Pathology Practice

this past summer. Toby served on the faculty of UNM Departments of Pathology and Internal Medicine where he

National Association of Medical Examiners 2019 Interim Meeting: Postmortem Radiology

performed research in the molecular mechanisms of antibiotic resistance and was Associate Professor of Pathology,

Date: February 19, 2019 1:00PM-5:00PM

Vice Chairman of the Department of Pathology, and Chief of Laboratory Services at the Veterans Administration

Location: Hyatt Regency Baltimore Inner Harbor

Hospital, from 1984 – 1992. Toby went on to work as Senior Vice-President and Chief Medical Officer, and an Officer
of the Board of Directors, at Lovelace Health Systems until 2003. He then left New Mexico to work for the Center

JUDY CANNON, P HD

of Disease Control where he most recently worked as Director of the Division of Preparedness and Emerging

Topic: Modeling T cell motion in tissues during immune responses

Infectious (DPEI) in the National Center for Emerging and Zoonotic Infectious Diseases (NCEZID). Toby came back

Platform: Member Organized Session: Multiscale Modeling of Biophysical Systems

to UNM for a visit in October of 2014 as the Keynote speaker at the SOM Pathology Department’s 50th Anniversary

Date: March 5, 2019 4:00PM- 6:00PM

celebration.

Location: Baltimore Convention Center

In his honor, a UNM Memorial Scholarship Fund has been established to aid students with significant financial need,

DOUGLAS P. CLAR K, MD

addressing one of Toby’s great passions. More information on the fund is available at: https://www.unmfund.org/

Topic: Deep Learning for Pathologists: a tutorial.

fund/toby-merlin/.

Co-chair of session at USCAP Annual Meeting
Date: March 18, 2019 8:00 AM-11:30 AM

Toby was well respected in his field and will be greatly missed by his co-workers and the entire medical community.
We extend our deepest sympathy to his family, friends, and colleagues.

ANGELA WANDINGER -NESS, P HD
Topic: Novel Rac1 Therapeutic for Cancer
Science2Startup Symposium
Date: April 23, 2019
Location: Broad Institute, Cambridge, MA.
DIANE LIDKE, P HD
Topic: Imaging the Early Events of Signal Transduction
Frontiers in Imaging Science II
Date: May 1st-4th, 2019
Location: Janelia Farms Research Campus, Ashburn, VA
DIANE LIDKE, P HD
Topic: Imaging protein dynamics during IgE receptor signaling
FASEB: The IgE and Allergy Conference: From Mechanism to Therapy
Date: July 7-12, 2019
Location: Scottsdale, AZ

continues on page 13
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M AKE A GIFT

continued from page 12

Your gift today impacts healthcare and research for tomorrow. Please consider making a recurring, one time, or

KAT HRYN FOUCA R , MD

legacy donation to one of the following funds:

Topic: 40th Annual Pathology Seminar
Date: Febuary 10th-15th, 2019

THE FOUCA R EN DOWMEN T

Location: Snowmass, CO

Invest in future Pathologists. Recruiting and training highly proficient Pathology residents and fellows is a top
KAT HRYN FOUCA R , MD

priority.

Topic: Tutorial on Neoplastic Hematopathology

VISIT: The Foucar Endowment

Date: January 21st-25th, 2019
Location: Naples, FL

THE GEOR GE D. MON TOYA R ESEA R CH SCHO L A RSHIP F U N D

JAY RAVA L , M D

Encourage UNM students to pursue a career in biomedical research.

Topic: Apheresis RBC Exchange and Sickle Cell Disease

VISIT: The George D. Montoya Research Scholarship Fund

Date: February 2019
Location: University of Texas

THE THOMAS M. WI LLI A MS & MA R GA R ET G. WIL L IA MS
EN DOWMEN T FOR EDUCATI ON A N D TR A I N I N G

JAY RAVA L , M D
Topic: Therapeutic Plasma Exchange and Myasthenia Gravis

Support the greatest educational and training needs within the Department of Pathology.

Date: March 2019

VISIT: The Dr. Thomas M. Williams & Margaret G. Williams Endowment for Education and Training

University of Massachusetts
JAY RAVA L , M D

DON ATE

Topics: Extracorporeal Photopheresis; Innovative Concepts and Treatments for Patients with Sickle Cell Disease;

Donate by credit card through the UNM Foundation website. Specific links to each Pathology fund are listed at

Immunologic Impact on TPE in Neurologic Disorders

pathology.unm.edu/make-a-gift

Date: May 2019
Location: American Society for Apheresis Annual Meeting

Donate by check, estate planning, bequest, charitable annuity, insurance gift, charitable trust and more, by
contacting Amanda Bassett, Director of Advancement and Alumni Relations for the UNM School of Medicine at

NE W FACULT Y M E M B ER S

(505) 272-5700 or abassett@salud.unm.edu.

Thank you for thinking of The University of New Mexico Department of Pathology funds as you generously give!

M A RA STE I N KA MP, P H D, Assistant Professor, July 25, 2018
L AUREN D E C KE R , MD, Assistant Professor, August 27, 2018
EMI LY VO L P I C E L L I , PA ( AS C P ), Lecturer II, August 31, 2018
M A RI A N ROL L I N S - R AVA L , MD, MP H, Associate Professor, October 1, 2018
JAY RAVA L , M D, Associate Professor, October 22, 2018
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Please share your news with: William F. Collins: wfcollins@salud.unm.edu

For more information on our department, please visit our website:
pathology.unm.edu

